Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…
Prowess Inc.
(https://prowess.com) 📸 Data Snapshot: May 24, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Home – Prowess Inc. (https://prowess.com)
Title
Home – Prowess Inc.
H2 USEFUL LINKS
H2 USEFUL LINKS
H2 NEWSLETTER
NAV_HEADER_REPEATED Support – Prowess Inc. (https://prowess.com/contact-us/support/)
Title
Support – Prowess Inc.
H2 CONTACT US
H2 Support
H2 USEFUL LINKS
H2 USEFUL LINKS
H2 NEWSLETTER
H3 Prowess Support Center
H3 PHONE
H3 EMAIL
H3 Remote Support
H3 How-To Videos
NAV_HEADING_FOOTER Conferences & Events – Prowess Inc. (https://prowess.com/media/conferences-events/)
Title
Conferences & Events – Prowess Inc.
H2 MEDIA
H2 Conferences & Events
H2 USEFUL LINKS
H2 USEFUL LINKS
H2 NEWSLETTER
H3 Conferences & Events
H3 ASTRO 2026
H3 ASTRO 2025
H3 ALATRO IX (2024)
H3 ASTRO 2024
H3 ESTRO meets Asia 2024
H3 ISRS 2024
NAV_HEADING_FOOTER Press Releases – Prowess Inc. (https://prowess.com/media/press-releases/)
Title
Press Releases – Prowess Inc.
H2 MEDIA
H2 Press Releases
H2 USEFUL LINKS
H2 USEFUL LINKS
H2 NEWSLETTER
H3 Prowess Inc. Announces Successful Relocation and Completion of ISO 13485 Audit at New Facility
H3 Prowess Inc. Receives Official Registration from Colombia’s INVIMA
H3 Prowess Inc. Announces FDA Clearance for Panther TPS 5.9 – A Next-Generation Radiation Therapy Planning System
H3 Prowess, Inc. Announces FDA 510(k) Clearance of Panther OIS
H3 Prowess, Inc. Receives FDA 510(k) Clearance for Panther Stereotactic Radiation Therapy System
H4 Press Releases
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE · THIN (https://prowess.com) Home – Prowess Inc.
Skip to content Prowess Inc. is a leading innovator of radiation oncology software solutions designed and developed in the San Francisco Bay Area. About Us Prowess' Panther TPS encompasses a large variety of planning modules including: VMAT, IMRT, 3DCRT and Brachy. TPS Info Prowess’ Panther OIS provides a single software solution for oncology centers to simplify operate their facilities efficiently. OIS Info
454 chars
SUB-PAGE · THIN (https://prowess.com/contact-us/support/) Support – Prowess Inc.
Skip to content [H2] CONTACT US [H2] Support [H3] Prowess Support Center Get the help you need: quickly, reliably, and from the experts who know Panther best.Whether you’re looking to troubleshoot a software issue, access technical documentation, or speak to a support representative, we’re here to assist you every step of the way. [H3] PHONE (925) 405-6556 [H3] EMAIL support@prowess.com [H3] Remote Support Prowess offers active customers remote support.Click the button below (or this link) and choose to save the file to a location you can easily locate. [H3] How-To Videos Prowess has created a number of videos to help customer with the most common support questions. Click the image below (or this link) to visit our YouTube page.
778 chars
SUB-PAGE · THIN (https://prowess.com/media/conferences-events/) Conferences & Events – Prowess Inc.
Skip to content [H2] MEDIA [H2] Conferences & Events [H3] Conferences & Events [H3] ASTRO 2026 [H3] ASTRO 2025 [H3] ALATRO IX (2024) [H3] ASTRO 2024 [H3] ESTRO meets Asia 2024 [H3] ISRS 2024
333 chars
SUB-PAGE (https://prowess.com/media/press-releases/) Press Releases – Prowess Inc.
Skip to content [H2] MEDIA [H2] Press Releases [H4] Press Releases Here you can download our press releases in the PDF file format. You will need the latest version of Adobe Reader to view these files. This is a free download. [H3] Prowess Inc. Announces Successful Relocation and Completion of ISO 13485 Audit at New Facility June 26, 2024 Concord, CA – Prowess Inc., a leading provider of innovative medical device solutions, is pleased to announce the successful relocation to its new state-of-the-art facility and the completion of a comprehensive ISO 13485 audit with no major or minor findings. This significant milestone underscores the company’s continued commitment to quality and operational excellence. The new facility, located at 5129 Commercial Cir. Concord, CA 94520, is designed to enhance operational efficiency, support future growth, and foster innovation in the development of cutting-edge medical technologies. With expanded production capabilities and upgraded infrastructure, Prowess is better positioned to meet the evolving needs of its customers and industry partners. “The successful completion of the ISO 13485 audit at our new location demonstrates our unwavering focus on maintaining the highest quality standards throughout our operations,” said Sophia Brown, Regulatory Affairs Manager at Prowess Inc. “This achievement reflects the hard work and dedication of our entire team, and we are excited about the opportunities this new facility brings.” ISO 13485 certification is a globally recognized standard for quality management systems in the medical device industry. The audit process involves rigorous assessments of a company’s processes, documentation, and adherence to regulatory requirements, ensuring the consistent delivery of safe and effective products. The relocation to the new facility was completed on time, with minimal disruption to ongoing operations. The facility features modernized production areas, dedicated R&D spaces, and enhanced logistics capabilities, enabling Prowess to better serve its growing customer base. Looking ahead, Prowess remains committed to continuous improvement and excellence in quality management. The company plans to leverage the new facility to accelerate product development, expand its portfolio, and strengthen partnerships across the medical device industry. For more information about Prowess Inc. and its products, please visit www.prowess.com or call 925-356-0360. [H3] Prowess Inc. Receives Official Registration from Colombia’s INVIMA January 10, 2024 Concord, CA – Prowess is proud to announce that it has received official registration approval from Colombia’s Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA). This significant achievement marks a milestone in the company’s commitment to providing high-quality products to the international market. The registration, valid for a period of ten (10) years, allows the distribution and commercialization of Panther TPS in Colombia. The product has undergone a comprehensive verification process by INVIMA, ensuring compliance with national health and safety regulations. “We are honored to receive this certification, which reinforces our dedication to delivering safe and effective products/services to customers in Colombia,” said Rick Smith, Director of Sales and Marketing. “This milestone opens up new opportunities for us to expand our presence in Latin America and continue offering solutions that meet the highest standards.” Prowess looks forward to serving the Colombian market and contributing to the advancement of radiation oncology solutions in the region. For more information or to schedule a product demonstration, please visit www.prowess.com or contact our support team at (925) 356-0360. [H3] Prowess Inc. Announces FDA Clearance for Panther TPS 5.9 – A Next-Generation Radiation Therapy Planning System December 15, 2023 Concord, CA – Prowess Inc., a leader in innovative radiation therapy solutions, is pleased to announce the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its latest version of the Panther Treatment Planning System (TPS), version 5.9. This clearance marks a significant milestone in Prowess’ commitment to advancing precision radiation therapy for cancer patients worldwide. The Panther TPS 5.9 offers a cutting-edge, fully integrated platform for radiation therapy planning, supporting highly complex treatment modalities including Intensity-Modulated Radiation Therapy (IMRT), Arc Therapy, and Stereotactic Radiotherapy. Designed for use by radiation oncologists, physicists, and dosimetrists, the system facilitates optimal treatment planning through precise dose calculations and advanced imaging integration. Key Features of Panther TPS 5.9: Comprehensive Treatment Modules: The software includes several advanced modules such as: IMRT Module: Enables precise planning for intensity-modulated radiation therapy using external photon beams. ProArc Module: Facilitates the creation of treatment plans for intensity-modulated arc radiation therapy. Stereotactic Module: Supports highly precise and targeted radiation therapy, critical for advanced cancer cases. Expanded Platform Compatibility: Now supporting Windows Server alongside Windows 10, ensuring greater flexibility for healthcare institutions. Validated Performance and Safety: Panther TPS 5.9 underwent extensive in-house verification and validation testing, demonstrating its equivalence in safety and effectiveness compared to its predicate device, Panther Stereotactic. “The FDA clearance of Panther TPS 5.9 underscores our dedication to improving patient outcomes through technological innovation,” said Rachel Scarano, Regulatory Affairs Manager at Prowess Inc. “This version is built to meet the demanding requirements of modern radiation therapy, enabling clinicians to deliver safe, effective, and personalized treatments.” Commitment to Quality and SafetyProwess Inc. maintains stringent quality assurance processes in compliance with FDA regulations and ISO 13485 standards. The company has conducted comprehensive risk assessments and implemented advanced mitigation measures to ensure the safety and efficacy of Panther TPS 5.9. About Prowess Inc.Prowess Inc. is a medical technology company specializing in radiation therapy software for cancer treatment. Founded on a mission to enhance precision medicine, Prowess offers innovative solutions that empower healthcare providers to improve cancer care. For more information, please visit www.prowess.com or contact:Media ContactRachel ScaranoRegulatory Affairs ManagerProwess Inc.Tel: (925) 356-0360Email: Rachel.scarano@prowess.com [H3] Prowess, Inc. Announces FDA 510(k) Clearance of Panther OIS September 28, 2021 Concord, CA – Prowess Inc., a leading provider of advanced medical technology solutions, is proud to announce that its Panther OIS (Oncology Information System) has received clearance from the U.S. Food and Drug Administration (FDA) under Section 510(k) of the Federal Food, Drug, and Cosmetic Act. The Panther OIS has been cleared as a Class II medical device under regulation number 21 CFR 892.5050, designated for use in medical charged-particle radiation therapy systems. The FDA’s substantial equivalence determination authorizes the Panther OIS to be marketed and used within the general controls provisions of the Act, ensuring compliance with critical regulatory requirements such as device registration, listing, and good manufacturing practices. This clearance signifies a major milestone in Prowess’ ongoing commitment to enhancing oncology care through innovative and reliable solutions. The Panther OIS is designed to streamline clinical workflows and improve the delivery of oncology treatment, offering healthcare providers enhanced tools for patient management and radiation therapy coordination. “We are thrilled to receive FDA clearance for Panther OIS, marking a pivotal step forward in our mission to empower oncology professionals with cutting-edge technology,” said Rachel Scarano, Regulatory Affairs Manager. “This clearance underscores our dedication to delivering high-quality solutions that meet stringent regulatory standards and improve patient outcomes.” For more information about the Panther OIS or Prowess’ oncology solutions, please visit www.prowess.com or contact our support team at (925) 356-0360. [H3] Prowess, Inc. Receives FDA 510(k) Clearance for Panther Stereotactic Radiation Therapy System April 27, 2020 Concord, CA – Prowess, Inc., a leading provider of advanced medical technology solutions, is proud to announce that its Panther Stereotactic Radiation Therapy System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) under regulation number 21 CFR 892.5050. This clearance confirms that Panther Stereotactic is substantially equivalent to legally marketed predicate devices and can now be marketed in the United States. The Panther Stereotactic system, classified as a Class II medical device, offers precise medical charged-particle radiation therapy planning. It is designed to plan for targeted radiation treatment, ensuring accuracy and minimizing exposure to surrounding healthy tissues. The FDA’s decision, following a comprehensive review of the submission (K193459), highlights the innovative design and reliability of the Panther Stereotactic system. This clearance underscores Prowess, Inc.’s commitment to advancing medical technology and improving outcomes for patients undergoing radiation therapy. “We are thrilled to receive this important regulatory milestone for Panther Stereotactic,” said John Nguyen, CEO at Prowess, Inc. “This clearance allows us to bring cutting-edge radiation therapy solutions to healthcare providers, enhancing their ability to treat complex cases with greater precision and confidence.”
10018 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
18Review mentions (all pages)
0External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 4 | 0 |
| /contact-us/support/ | 4 | 0 |
| /media/conferences-events/ | 4 | 0 |
| /media/press-releases/ | 6 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "http://prowess.com/",
"url": "http://prowess.com/",
"name": "Home - Prowess Inc.",
"isPartOf": {
"@id": "http://prowess.com/#website"
},
"about": {
"@id": "http://prowess.com/#organization"
},
"datePublished": "2019-01-23T13:51:57+00:00",
"dateModified": "2019-02-27T09:58:50+00:00",
"breadcrumb": {
"@id": "http://prowess.com/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"http://prowess.com/"
]
}
]
},
{
"@type": "BreadcrumbList",
"@id": "http://prowess.com/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home"
}
]
},
{
"@type": "WebSite",
"@id": "http://prowess.com/#website",
"url": "http://prowess.com/",
"name": "Prowess Inc.",
"description": "Cooperate site with product information.",
"publisher": {
"@id": "http://prowess.com/#organization"
},
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "http://prowess.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
},
{
"@type": "Organization",
"@id": "http://prowess.com/#organization",
"name": "Prowess Inc.",
"url": "http://prowess.com/",
"logo": {
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "http://prowess.com/#/schema/logo/image/",
"url": "https://prowess.com/wp-content/uploads/2019/01/prowess_logo.png",
"contentUrl": "https://prowess.com/wp-content/uploads/2019/01/prowess_logo.png",
"width": 281,
"height": 57,
"caption": "Prowess Inc."
},
"image": {
"@id": "http://prowess.com/#/schema/logo/image/"
}
}
]
}
/contact-us/support/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "http://prowess.com/contact-us/support/",
"url": "http://prowess.com/contact-us/support/",
"name": "Support - Prowess Inc.",
"isPartOf": {
"@id": "http://prowess.com/#website"
},
"primaryImageOfPage": {
"@id": "http://prowess.com/contact-us/support/#primaryimage"
},
"image": {
"@id": "http://prowess.com/contact-us/support/#primaryimage"
},
"thumbnailUrl": "http://prowess.com/wp-content/uploads/2019/07/qs-button.png",
"datePublished": "2019-01-24T15:45:10+00:00",
"dateModified": "2025-07-25T23:48:55+00:00",
"breadcrumb": {
"@id": "http://prowess.com/contact-us/support/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"http://prowess.com/contact-us/support/"
]
}
]
},
{
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "http://prowess.com/contact-us/support/#primaryimage",
"url": "https://prowess.com/wp-content/uploads/2019/07/qs-button.png",
"contentUrl": "https://prowess.com/wp-content/uploads/2019/07/qs-button.png",
"width": 308,
"height": 78
},
{
"@type": "BreadcrumbList",
"@id": "http://prowess.com/contact-us/support/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "http://prowess.com/"
},
{
"@type": "ListItem",
"position": 2,
"name": "Contact Us",
"item": "https://prowess.com/contact-us/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Support"
}
]
},
{
"@type": "WebSite",
"@id": "http://prowess.com/#website",
"url": "http://prowess.com/",
"name": "Prowess Inc.",
"description": "Cooperate site with product information.",
"publisher": {
"@id": "http://prowess.com/#organization"
},
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "http://prowess.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
},
{
"@type": "Organization",
"@id": "http://prowess.com/#organization",
"name": "Prowess Inc.",
"url": "http://prowess.com/",
"logo": {
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "http://prowess.com/#/schema/logo/image/",
"url": "https://prowess.com/wp-content/uploads/2019/01/prowess_logo.png",
"contentUrl": "https://prowess.com/wp-content/uploads/2019/01/prowess_logo.png",
"width": 281,
"height": 57,
"caption": "Prowess Inc."
},
"image": {
"@id": "http://prowess.com/#/schema/logo/image/"
}
}
]
}
/media/conferences-events/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://prowess.com/media/conferences-events/",
"url": "https://prowess.com/media/conferences-events/",
"name": "Conferences & Events - Prowess Inc.",
"isPartOf": {
"@id": "http://prowess.com/#website"
},
"datePublished": "2019-01-24T12:01:16+00:00",
"dateModified": "2019-02-22T16:12:04+00:00",
"breadcrumb": {
"@id": "https://prowess.com/media/conferences-events/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://prowess.com/media/conferences-events/"
]
}
]
},
{
"@type": "BreadcrumbList",
"@id": "https://prowess.com/media/conferences-events/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "http://prowess.com/"
},
{
"@type": "ListItem",
"position": 2,
"name": "Private: Media",
"item": "https://prowess.com/?page_id=18"
},
{
"@type": "ListItem",
"position": 3,
"name": "Conferences & Events"
}
]
},
{
"@type": "WebSite",
"@id": "http://prowess.com/#website",
"url": "http://prowess.com/",
"name": "Prowess Inc.",
"description": "Cooperate site with product information.",
"publisher": {
"@id": "http://prowess.com/#organization"
},
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "http://prowess.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
},
{
"@type": "Organization",
"@id": "http://prowess.com/#organization",
"name": "Prowess Inc.",
"url": "http://prowess.com/",
"logo": {
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "http://prowess.com/#/schema/logo/image/",
"url": "https://prowess.com/wp-content/uploads/2019/01/prowess_logo.png",
"contentUrl": "https://prowess.com/wp-content/uploads/2019/01/prowess_logo.png",
"width": 281,
"height": 57,
"caption": "Prowess Inc."
},
"image": {
"@id": "http://prowess.com/#/schema/logo/image/"
}
}
]
}
/media/press-releases/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://prowess.com/media/press-releases/",
"url": "https://prowess.com/media/press-releases/",
"name": "Press Releases - Prowess Inc.",
"isPartOf": {
"@id": "http://prowess.com/#website"
},
"datePublished": "2019-01-25T08:42:55+00:00",
"dateModified": "2019-02-22T16:12:56+00:00",
"breadcrumb": {
"@id": "https://prowess.com/media/press-releases/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://prowess.com/media/press-releases/"
]
}
]
},
{
"@type": "BreadcrumbList",
"@id": "https://prowess.com/media/press-releases/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "http://prowess.com/"
},
{
"@type": "ListItem",
"position": 2,
"name": "Private: Media",
"item": "https://prowess.com/?page_id=18"
},
{
"@type": "ListItem",
"position": 3,
"name": "Press Releases"
}
]
},
{
"@type": "WebSite",
"@id": "http://prowess.com/#website",
"url": "http://prowess.com/",
"name": "Prowess Inc.",
"description": "Cooperate site with product information.",
"publisher": {
"@id": "http://prowess.com/#organization"
},
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "http://prowess.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
},
{
"@type": "Organization",
"@id": "http://prowess.com/#organization",
"name": "Prowess Inc.",
"url": "http://prowess.com/",
"logo": {
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "http://prowess.com/#/schema/logo/image/",
"url": "https://prowess.com/wp-content/uploads/2019/01/prowess_logo.png",
"contentUrl": "https://prowess.com/wp-content/uploads/2019/01/prowess_logo.png",
"width": 281,
"height": 57,
"caption": "Prowess Inc."
},
"image": {
"@id": "http://prowess.com/#/schema/logo/image/"
}
}
]
}
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Information Density
0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence
0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof
0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint
0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority
0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score
0 / 100
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Information Density
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Semantic Alignment
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Trust & Proof
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Commodity Fingerprint
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Identity & Authority
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS
Based on 784 businesses audited.
✓ Less BS than average
Prowess Inc. has 1.7 points less BS than the average for Medical Devices, Pharma & Biotech.
BS Detector
Medical Devices, Pharma & Biotech BS: Prowess Inc. (prowess.com)
https://prowess.com
📍 Industry: Medical Devices, Pharma & Biotech
39
BS / 100
Prowess Inc. is a technically legitimate entity suffering from a Trust Theatre hangover and an aging web architecture. While their regulatory evidence is ironclad and substantive, their marketing delivery is hampered by template-based boilerplate and technical schema inconsistencies.
Info Density
Power-words vs. Substance ratio.
6
20% BS
Semantic Coherence
Homepage promise vs. Sub-page reality.
4
20% BS
Trust & Proof
Verifiable evidence vs. Trust Theatre.
12
60% BS
Commodity Fingerprint
Detection of industry clichés/templates.
9
60% BS
Identity & Authority
Expert verifiability & Schema depth.
8
53% BS
Fix the heading hierarchy immediately by adding H1 tags that include the brand and primary product names. Hyperlink the FDA 510(k) numbers directly to the official government database to provide verifiable proof paths. Remove the hidden review counts from the JSON-LD schema if you cannot display verified, dated testimonials on the visible page. Implement Person schema for named executives to bridge the authority gap.
Prowess Inc. aligns perfectly with the Medical Device and radiation oncology software sector. The terminology used, including VMAT, IMRT, and 510(k) clearance, confirms a highly specialized technical focus and regulatory awareness required for this category.
“The score is primarily driven by Trust Theatre flags (8/8) and authority gaps resulting from technical implementation flaws like missing H1s and schema mismatches. The core substance regarding FDA clearances is actually quite high, which prevented the score from entering the 'High BS' range.”
Verified Analysis Date: May 24, 2026
© 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution
This training module utilizes a snapshot of public data from Prowess Inc., captured on May 24, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Prowess Inc.: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://prowess.com to view the most current version of its content and learn from the source what this company is about and what it offers.